Related Experiment Video

Updated: Jul 30, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.2K

Metastatic Castration-Resistant Prostate Cancer, Immune Checkpoint Inhibitors, and Beyond

Sree M Lanka1, Nicholas A Zorko2, Emmanuel S Antonarakis2

  • 1Deming Department of Medicine, Tulane University, New Orleans, LA 70112, USA.

Current Oncology (Toronto, Ont.)
|May 15, 2023
PubMed

Insights

Immune checkpoint inhibitors show limited success in prostate cancer due to its "cold" tumor environment. Research is exploring combination therapies and novel targets like B7-H3 to improve treatment for metastatic castration-resistant prostate cancer.

Area of Science:

  • Oncology
  • Immunotherapy
  • Genitourinary Malignancies

Background:

  • Immune checkpoint inhibitors (ICIs) have transformed genitourinary cancer treatment.
  • Prostate cancer's immunologically "cold" nature limits immunotherapy efficacy.
  • Pembrolizumab is approved for select metastatic castration-resistant prostate cancer (mCRPC) patients with MSI-H/dMMR or TMB-H.

Purpose of the Study:

  • To review current ICI monotherapy and combination trials in mCRPC.
  • To explore novel immunotherapy strategies and targets for mCRPC.
  • To summarize the therapeutic landscape of immunotherapies in prostate cancer.

Main Methods:

  • Literature review of clinical trials involving ICIs in mCRPC.
  • Analysis of ongoing and planned combination therapy studies.
  • Examination of emerging immunotherapy targets, including B7-H3.

Main Results:

  • Limited efficacy of current ICI monotherapy in prostate cancer.
  • Promising results from ongoing combination trials (e.g., with radioligands, PARP inhibitors).
  • B7-H3 identified as a potential novel immunotherapy target.

Conclusions:

  • Combinatorial approaches are crucial for enhancing ICI effectiveness in mCRPC.
  • Targeting novel checkpoints like B7-H3 may expand treatment options.
  • Further research into immunotherapy combinations is essential for advancing mCRPC treatment.
Keywords:
immune checkpoint inhibitorsimmunotherapy combinationsmetastatic castration-resistant prostate cancer

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.9K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

455

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
587
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
449
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K